Thursday, 15 October 2026European Markets

Euro Hits $1.13, 14-Year High Against Dollar as European Exporters Gain Pricing Power

The euro reached €1.13 against the British pound, its strongest level since April 2023, as the dollar fell to its lowest point since 2022. The euro has appreciated 14% against the dollar in 2025, strengthening European manufacturers' competitive position in global markets. Currency shifts stem from Federal Reserve leadership uncertainty ahead of Jerome Powell's June 2026 replacement and ongoing US policy debates.

Euro Hits $1.13, 14-Year High Against Dollar as European Exporters Gain Pricing Power
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro reached €1.13 against the British pound and strengthened 14% versus the dollar in 2025, reaching its highest levels since 2011 as dollar weakness reshapes European export dynamics.

European manufacturers now hold stronger pricing power in dollar-denominated markets. German industrial exporters, French luxury goods producers, and Italian machinery makers can undercut US and Asian competitors while maintaining euro-based profit margins.

The British pound fell 0.4% to €1.13 and dropped 0.5% to $1.3086 against the dollar. Currency analyst Jordan Rochester at Mizuho Bank predicts the pound could fall below $1.30 as fiscal pressures mount.

Dollar decline accelerated amid uncertainty over Federal Reserve leadership. Jerome Powell's term ends June 2026, and markets have no clarity on his replacement's monetary policy stance. This leadership vacuum compounds existing concerns about US fiscal trajectory and geopolitical positioning.

Simon Phillips, managing director at No1 Currency, noted mounting pressure on sterling as investors reassess European versus Anglo-American currency positions. UK 30-year gilt yields climbed to 5.21%, the highest since 1998.

Safe-haven flows benefited the Swiss franc as defensive positioning increased. The franc traditionally attracts capital during periods of dollar weakness and policy uncertainty.

European equity markets responded positively. The Stoxx 600 reached a record 583.4 points, up 0.6%. Germany's DAX gained 0.9% and France's CAC 40 rose 0.7%. Export-heavy indices benefit when euro strength doesn't exceed competitiveness thresholds.

Currency shifts also reflect progress on Iran-US nuclear negotiations, which could reshape oil markets and commodity-linked currency valuations. Brent crude traded above $65 per barrel as geopolitical risk premiums adjusted.

Neil Wilson, analyst at Saxo Markets, warned of fiscal instability risks across major economies. Markets are repositioning for continued dollar weakness through 2026, with implications for European trade balances, corporate earnings, and cross-border investment flows.

The FTSE 100 closed at a record 9,911 points despite sterling weakness, as British multinationals benefit from overseas revenue translated back into pounds at favorable rates.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com